Effect of Brimonidine on Corneal Thickness
- Conditions
- Impact of Brimonidine on the Cornea
- Interventions
- Drug: placebo
- Registration Number
- NCT01250236
- Lead Sponsor
- Augenarztpraxis Breisach
- Brief Summary
Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors there are only few studies available on the impact brimonidine has on the cornea. The aim of the study is to find out
1. whether topical administration of brimonidine results in interaction with corneal alpha-2 adrenoceptors in terms of an increase in corneal thickness and
2. whether there are any differences between the response corneal epithelium, stroma and endothelium show to alpha-2 adrenoceptor stimulation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- healthy, 18-99 years, normal ophthalmologic history, consent to participate in the study
Exclusion Criteria
- any serious medical or neurologic conditions and/or regular use of local or systemic medications
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description verum brimonidine 0.1% brimonidine 0.1% eye drops twice daily placebo placebo sodium hyaluronate 1.8mg/ml eye drops twice daily
- Primary Outcome Measures
Name Time Method corneal thickness 5 days
- Secondary Outcome Measures
Name Time Method intraocular pressure 5 days
Trial Locations
- Locations (1)
Augenarztpraxis
🇩🇪Breisach, Baden-Wuerttemberg, Germany